These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27297910)

  • 41. Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.
    Zhou Z; Dai C; Liu WX
    Hepatogastroenterology; 2015; 62(138):309-18. PubMed ID: 25916055
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inducing remission of ulcerative colitis: are clinicians better equipped than ever?
    Armuzzi A; Felice C
    Expert Rev Gastroenterol Hepatol; 2013 Feb; 7(2):95-7. PubMed ID: 23363258
    [No Abstract]   [Full Text] [Related]  

  • 43. Efficacy and safety of infliximab in treating patients with ulcerative colitis: experiences from a single medical center in southern China.
    Zhou YL; Xie S; Wang P; Zhang T; Lin MY; Tan JS; Zhi FC; Jiang B; Chen Y
    J Dig Dis; 2014 Sep; 15(9):483-90. PubMed ID: 24828856
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Infliximab for ulcerative colitis in children and adolescents.
    McGinnis JK; Murray KF
    J Clin Gastroenterol; 2008 Sep; 42(8):875-9. PubMed ID: 18645529
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ulcerative colitis: conservative management and long-term effects.
    Kühbacher T; Schreiber S; Fölsch UR
    Langenbecks Arch Surg; 2004 Oct; 389(5):350-3. PubMed ID: 15133672
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Anti-TNF-alpha therapy in ulcerative colitis].
    Lakatos PL; Lakatos L
    Orv Hetil; 2008 May; 149(20):921-7. PubMed ID: 18467261
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
    Feagan BG; Greenberg GR; Wild G; Fedorak RN; Paré P; McDonald JW; Dubé R; Cohen A; Steinhart AH; Landau S; Aguzzi RA; Fox IH; Vandervoort MK
    N Engl J Med; 2005 Jun; 352(24):2499-507. PubMed ID: 15958805
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab.
    Taxonera C; Estellés J; Fernández-Blanco I; Merino O; Marín-Jiménez I; Barreiro-de Acosta M; Saro C; García-Sánchez V; Gento E; Bastida G; Gisbert JP; Vera I; Martinez-Montiel P; Garcia-Morán S; Sánchez MC; Mendoza JL
    Aliment Pharmacol Ther; 2011 Feb; 33(3):340-8. PubMed ID: 21133961
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Therapy of ulcerative colitis].
    Vavricka SR; Rogler G
    Praxis (Bern 1994); 2009 Feb; 98(4):209-12. PubMed ID: 19224489
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis.
    Olsen T; Goll R; Cui G; Christiansen I; Florholmen J
    Cytokine; 2009 May; 46(2):222-7. PubMed ID: 19286392
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.
    Vermeire S; O'Byrne S; Keir M; Williams M; Lu TT; Mansfield JC; Lamb CA; Feagan BG; Panes J; Salas A; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Tew GW; Luca D; Tang MT; Diehl L; Eastham-Anderson J; De Hertogh G; Perrier C; Egen JG; Kirby JA; van Assche G; Rutgeerts P
    Lancet; 2014 Jul; 384(9940):309-18. PubMed ID: 24814090
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment of servere ulcerative colitis].
    Weersma RK; van Dullemen HM; Kleibeuker JH; Ploeg RJ; Dijkstra G
    Ned Tijdschr Geneeskd; 2006 Jan; 150(1):12-7. PubMed ID: 16440618
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Infliximab in moderate to severe steroid-dependent or steroid-refractory ulcerative colitis].
    Mocciaro F; Orlando A; Scimeca D; Cottone M
    Recenti Prog Med; 2007 Nov; 98(11):560-4. PubMed ID: 18044405
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Editorial: Racial Difference in Efficacy of Golimumab in Ulcerative Colitis.
    Odufalu FD
    Inflamm Bowel Dis; 2023 Jun; 29(6):1010-1011. PubMed ID: 35986718
    [No Abstract]   [Full Text] [Related]  

  • 55. Nocardia and Aspergillus Coinfection in a Patient with Ulcerative Colitis during Golimumab Therapy.
    Alonso-Sierra M; Calvo M; González-Lama Y
    J Crohns Colitis; 2016 Sep; 10(9):1127-8. PubMed ID: 26944414
    [No Abstract]   [Full Text] [Related]  

  • 56. Infliximab avoiding colectomy and maintaining remission in pediatric immunosuppressive-naïve ulcerative colitis achieving remarkable mucosal healing.
    Sciaudone G; Pellino G; Guadagni I; Selvaggi F
    Panminerva Med; 2010 Mar; 52(1):91-2. PubMed ID: 20228729
    [No Abstract]   [Full Text] [Related]  

  • 57. Infliximab for refractory ulcerative colitis.
    Chey WY; Hussain A; Ryan C; Potter GD; Shah A
    Am J Gastroenterol; 2001 Aug; 96(8):2373-81. PubMed ID: 11513177
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
    Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ
    Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Infliximab for induction and maintenance therapy for ulcerative colitis.
    Moss AC; Farrell RJ
    Gastroenterology; 2006 Nov; 131(5):1649-51; discussion 1651. PubMed ID: 17067595
    [No Abstract]   [Full Text] [Related]  

  • 60. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.
    Su C; Salzberg BA; Lewis JD; Deren JJ; Kornbluth A; Katzka DA; Stein RB; Adler DR; Lichtenstein GR
    Am J Gastroenterol; 2002 Oct; 97(10):2577-84. PubMed ID: 12385442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.